Pharsight

1. Abraxane patent expiration

Application	Filing Date	Opposition Party	Legal Status

EP17165979A	2020-04-24	Generics (UK) Ltd	Revoked
EP17165979A	2020-04-09	Teva Pharmaceutical Industries Ltd	Revoked
EP06735710A	2012-08-02	MediGene Aktiengesellschaft	Revoked
EP06735710A	2012-08-01	Generics [UK] Limited	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7758891	BRISTOL MYERS	Combinations and modes of administration of therapeutic agents and combination therapy	Feb, 2026 (7 days ago)
US9101543	BRISTOL MYERS	Combinations and modes of administration of therapeutic agents and combination therapy	Feb, 2026 (7 days ago)
US8268348	BRISTOL MYERS	Combinations and modes of administration of therapeutic agents and combination therapy	Feb, 2026 (7 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-658)	Oct 11, 2015
New Indication(I-676)	Sep 06, 2016
Orphan Drug Exclusivity(ODE)	Sep 06, 2020
Orphan Drug Exclusivity(ODE-52)	Sep 06, 2020
M(M-14)	Dec 06, 2022
Pediatric Exclusivity(PED)	Jun 06, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of pancreatic cancer; Treatment of lung cancer

Dosage: POWDER

Strength	Submission Date	Expiration Date of Last Qualifying Patent	180-Day Status	First Applicant Approval	Generic Competition Status
25 mg / 5 mL 🔒 Unlock	11 Dec, 2015	27 Oct, 2024	Extinguished		Less

Strength	Dosage	Availability
100MG/VIAL	POWDER	Prescription

ABRAXANE family patents

2. Advair Hfa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444	GLAXO	Actuation indicator for a dispensing device	Feb, 2026 (2 days ago)

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 08 June, 2006

Treatment: NA

Dosage: AEROSOL, METERED

Strength	Dosage	Availability
0.045MG/INH;EQ 0.021MG BASE/INH	AEROSOL, METERED	Prescription
0.23MG/INH;EQ 0.021MG BASE/INH	AEROSOL, METERED	Prescription

ADVAIR HFA family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Auvi-q patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259539	KALEO	Devices, systems and methods for medicament delivery	Feb, 2026 (27 days ago)
US9278182	KALEO	Devices, systems and methods for medicament delivery	Feb, 2026 (27 days ago)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 17 November, 2017

Treatment: NA

Dosage: SOLUTION

Strength	Dosage	Availability
EQ 0.15MG/DELIVERY	SOLUTION	Prescription
EQ 0.3MG/DELIVERY	SOLUTION	Prescription
EQ 0.1MG/DELIVERY	SOLUTION	Prescription

AUVI-Q family patents

4. Briviact patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6911461	UCB	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses	Feb, 2026 (7 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 12, 2021
New Patient Population(NPP)	Aug 27, 2024

Drugs and Companies using BRIVARACETAM ingredient

NCE-1 date: 12 May, 2020

Market Authorisation Date: 12 May, 2016

Treatment: Treatment of partial-onset seizures in patients 4 years of age and older

Dosage: SOLUTION; TABLET

Strength	Submission Date	Expiration Date of Last Qualifying Patent	180-Day Status	First Applicant Approval	Generic Competition Status
25 mg / 5 mL 🔒 Unlock	12 May, 2020	21 Feb, 2026			Less
25 mg / 5 mL 🔒 Unlock	12 May, 2020	21 Feb, 2026			Less
25 mg / 5 mL 🔒 Unlock	12 May, 2020	21 Feb, 2026	Eligible	09 Jun, 2022	High

Strength	Dosage	Availability
10MG/ML	SOLUTION	Prescription
10MG	TABLET	Prescription
25MG	TABLET	Prescription
75MG	TABLET	Prescription
100MG	TABLET	Prescription
50MG/5ML (10MG/ML)	SOLUTION	Prescription
50MG	TABLET	Prescription

BRIVIACT family patents

5. Corlanor patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7361650	AMGEN	γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it	Feb, 2026 (6 days ago)
US7879842	AMGEN	Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it	Feb, 2026 (6 days ago)
US7361649	AMGEN	β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it	Feb, 2026 (6 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Apr 15, 2020
Pediatric Exclusivity(PED)	Oct 22, 2026
New Product(NP)	Apr 22, 2022
Orphan Drug Exclusivity(ODE-234)	Apr 22, 2026

Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient

NCE-1 date: 16 October, 2019

Market Authorisation Date: 15 April, 2015

Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride

Dosage: TABLET

Strength	Submission Date	Expiration Date of Last Qualifying Patent	180-Day Status	First Applicant Approval	Generic Competition Status
25 mg / 5 mL 🔒 Unlock	15 Oct, 2019	22 Feb, 2026	Eligible	30 Dec, 2021	High

Strength	Dosage	Availability
EQ 5MG BASE	TABLET	Discontinued
EQ 7.5MG BASE	TABLET	Discontinued

CORLANOR family patents

6. Corlanor patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7879842	AMGEN	Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it	Feb, 2026 (6 days ago)
US7361649	AMGEN	β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it	Feb, 2026 (6 days ago)
US7361650	AMGEN	γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it	Feb, 2026 (6 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Apr 15, 2020
Pediatric Exclusivity(PED)	Oct 22, 2026
New Product(NP)	Apr 22, 2022
Orphan Drug Exclusivity(ODE-234)	Apr 22, 2026

Drugs and Companies using IVABRADINE ingredient

NCE-1 date: 16 April, 2019

Market Authorisation Date: 22 April, 2019

Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride

Dosage: SOLUTION

Strength	Dosage	Availability
5MG/5ML (1MG/ML)	SOLUTION	Prescription

CORLANOR family patents

7. Dexilant patent expiration

Application	Filing Date	Opposition Party	Legal Status

EP10175046A	2016-06-02	Aechter, Bernd	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9011926	TAKEDA	Method for producing granules	Feb, 2026 (4 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jan 30, 2012
Pediatric Exclusivity(PED)	Jul 30, 2012
New Patient Population(NPP)	Jul 08, 2019

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE

Strength	Submission Date	Expiration Date of Last Qualifying Patent	180-Day Status	First Applicant Approval	Generic Competition Status
25 mg / 5 mL 🔒 Unlock	30 Nov, 2010	02 Aug, 2026	Extinguished		Less

Strength	Dosage	Availability
60MG	CAPSULE, DELAYED RELEASE	Prescription
30MG	CAPSULE, DELAYED RELEASE	Prescription

DEXILANT family patents

8. Dexilant Solutab patent expiration

Application	Filing Date	Opposition Party	Legal Status

EP10175046A	2016-06-02	Aechter, Bernd	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9011926	TAKEDA	Method for producing granules	Feb, 2026 (4 days ago)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE

Strength	Dosage	Availability
30MG	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE	Discontinued

DEXILANT SOLUTAB family patents

9. Dymista patent expiration

Application	Filing Date	Opposition Party	Legal Status

EP09075100A	2016-04-11	Sanovel IIaç San. ve Tic. A.S.	Revoked
EP09075101A	2014-10-29	Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi	Revoked
EP09075101A	2014-10-24	Sanovel IIaç San. ve Tic. A.S.	Revoked
EP03738280A	2010-01-14	Glaxo Group Limited	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8168620	January, 2020	Institution Denied	Cipla Limited et al.	GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
US8168620	February, 2017	Terminated-Settled	Cipla Limited	Argentum Pharmaceuticals LLC

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168620	MYLAN	Combination of azelastine and steroids	Feb, 2026 (4 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	May 01, 2015
New Patient Population(NPP)	Feb 20, 2018
Pediatric Exclusivity(PED)	Aug 20, 2018

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 01 May, 2012

Treatment: NA

Dosage: SPRAY, METERED

Strength	Submission Date	Expiration Date of Last Qualifying Patent	180-Day Status	First Applicant Approval	Generic Competition Status
25 mg / 5 mL 🔒 Unlock	13 Jun, 2014	24 Aug, 2026	Eligible	28 Apr, 2017	Less

Strength	Dosage	Availability
0.137MG/SPRAY;0.05MG/SPRAY	SPRAY, METERED	Prescription

DYMISTA family patents

10. Elepsia Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8535717	TRIPOINT	Pharmaceutical composition	Feb, 2026 (6 days ago)
US8425938	TRIPOINT	Pharmaceutical composition	Feb, 2026 (6 days ago)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 20 December, 2018

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

Strength	Dosage	Availability
1GM	TABLET, EXTENDED RELEASE	Discontinued
1.5GM	TABLET, EXTENDED RELEASE	Discontinued

ELEPSIA XR family patents

11. Evzio patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278182	KALEO	Devices, systems and methods for medicament delivery	Feb, 2026 (27 days ago)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION

Strength	Dosage	Availability
0.4MG/0.4ML (0.4MG/0.4ML)	SOLUTION	Discontinued

EVZIO family patents

12. Evzio (autoinjector) patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278182	KALEO	Devices, systems and methods for medicament delivery	Feb, 2026 (27 days ago)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION

Strength	Dosage	Availability
2MG/0.4ML (2MG/0.4ML)	SOLUTION	Discontinued

EVZIO (AUTOINJECTOR) family patents

13. Flovent Hfa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444	GLAXO	Actuation indicator for a dispensing device	Feb, 2026 (2 days ago)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 14 May, 2004

Treatment: NA

Dosage: AEROSOL, METERED

Strength	Submission Date	Expiration Date of Last Qualifying Patent	180-Day Status	First Applicant Approval	Generic Competition Status
25 mg / 5 mL 🔒 Unlock	29 Oct, 2021	26 Feb, 2026			Less
25 mg / 5 mL 🔒 Unlock	23 Dec, 2016	26 Feb, 2026			Less

Strength	Dosage	Availability
0.22MG/INH	AEROSOL, METERED	Prescription
0.11MG/INH	AEROSOL, METERED	Prescription

FLOVENT HFA family patents

14. Flyrcado patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9161997	GE HEALTHCARE	Contrast agents for myocardial perfusion imaging	Feb, 2026 (24 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 27, 2029

Drugs and Companies using FLURPIRIDAZ F-18 ingredient

NCE-1 date: 27 September, 2028

Market Authorisation Date: 27 September, 2024

Treatment: Method of positron emission tomography (pet) for cardiac imaging

Dosage: SOLUTION

Strength	Dosage	Availability
5-55mCi/ML	SOLUTION	Prescription

FLYRCADO family patents

15. Jublia patent expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7214506	November, 2016	Final Written Decision	Kaken Pharmaceutical Co., Ltd.	Acrux DDS Pty Ltd. et al.
US7214506	May, 2017	Terminated-Settled	Kaken Pharmaceutical Co., Ltd. et al.	Argentum Pharmaceuticals LLC et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214506	BAUSCH	Method for treating onychomycosis	Feb, 2026 (6 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 06, 2019
New Patient Population(NPP)	Apr 27, 2023

Drugs and Companies using EFINACONAZOLE ingredient

NCE-1 date: 06 June, 2018

Market Authorisation Date: 06 June, 2014

Treatment: Antimycotic uses, specifically treatment of onychomycosis

Dosage: SOLUTION

Strength	Submission Date	Expiration Date of Last Qualifying Patent	180-Day Status	First Applicant Approval	Generic Competition Status
25 mg / 5 mL 🔒 Unlock	06 Jun, 2018	02 Oct, 2034	Eligible	16 Dec, 2020	High

JUBLIA family patents

16. Kerydin patent expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9549938	November, 2017	Final Written Decision	Anacor Pharmaceuticals, Inc. et al.	FlatWing Pharmaceuticals, LLC et al.
US9566289	November, 2017	Final Written Decision	Anacor Pharmaceuticals, Inc. et al.	FlatWing Pharmaceuticals, LLC et al.
US9566290	November, 2017	Final Written Decision	Anacor Pharmaceuticals, Inc. et al.	FlatWing Pharmaceuticals, LLC et al.
US9572823	November, 2017	Final Written Decision	Anacor Pharmaceuticals, Inc. et al.	FlatWing Pharmaceuticals, LLC et al.
US9549938	July, 2018	Terminated	Pfizer Inc.	Mylan Pharmaceuticals Inc. et al.
US9566289	July, 2018	Terminated	Pfizer Inc.	Mylan Pharmaceuticals Inc. et al.
US9566290	July, 2018	Terminated	Pfizer Inc.	Mylan Pharmaceuticals Inc. et al.
US9572823	July, 2018	Terminated	Pfizer Inc.	Mylan Pharmaceuticals Inc. et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566289	ANACOR	Boron-containing small molecules	Feb, 2026 (12 days ago)
US9566290	ANACOR	Boron-containing small molecules	Feb, 2026 (12 days ago)
US9549938	ANACOR	Boron-containing small molecules	Feb, 2026 (12 days ago)
US9572823	ANACOR	Boron-containing small molecules	Feb, 2026 (12 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 07, 2019
Pediatric Exclusivity(PED)	Jan 07, 2020

Drugs and Companies using TAVABOROLE ingredient

NCE-1 date: 07 January, 2019

Market Authorisation Date: 07 July, 2014

Treatment: Treatment of onychomychosis of a toenail caused by trichophyton rubrum or trichophyton mentagrophytes; Treatment of onychomycosis of a toenail

Dosage: SOLUTION

KERYDIN family patents

17. Onzetra Xsail patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11571531	CURRAX	Powder delivery devices	Feb, 2026 (5 days ago)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: Method of drug delivery via the nasal cavity

Dosage: POWDER

ONZETRA XSAIL family patents

18. Saxenda patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114833 (Pediatric)	NOVO NORDISK	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices	Feb, 2026 (15 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 25, 2015
New Product(NP)	Jan 25, 2017
New Patient Population(NPP)	Dec 04, 2023

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 25 January, 2014

Market Authorisation Date: 23 December, 2014

Treatment: NA

Dosage: SOLUTION

SAXENDA family patents

19. Skelaxin patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7122566	KING PHARMA	Metaxalone products, method of manufacture, and method of use	Feb, 2026 (22 days ago)

Drugs and Companies using METAXALONE ingredient

Market Authorisation Date: 01 January, 1982

Treatment: Treatment of musculoskeletal conditions

Dosage: TABLET

SKELAXIN family patents

20. Tekturna patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617595	LXO	Galenic formulations of organic compounds	Feb, 2026 (9 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 05, 2012
New Product(NP)	Nov 14, 2020
Pediatric Exclusivity(PED)	May 14, 2021

Drugs and Companies using ALISKIREN HEMIFUMARATE ingredient

NCE-1 date: 06 March, 2011

Market Authorisation Date: 05 March, 2007

Treatment: NA

Dosage: TABLET

TEKTURNA family patents

21. Victoza patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114833 (Pediatric)	NOVO NORDISK	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices	Feb, 2026 (15 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 25, 2015
M(M-115)	Apr 06, 2015
M(M-176)	Apr 22, 2019
New Indication(I-750)	Aug 25, 2020
New Patient Population(NPP)	Jun 17, 2022
Pediatric Exclusivity(PED)	Dec 17, 2022

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 17 December, 2021

Market Authorisation Date: 25 January, 2010

Treatment: NA

Dosage: SOLUTION

VICTOZA family patents

22. Vizimpro patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596162	PFIZER	Method for treating gefitinib resistant cancer	Feb, 2026 (26 days ago)
US10603314	PFIZER	Method for treating gefitinib resistant cancer	Feb, 2026 (26 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 27, 2023
Orphan Drug Exclusivity(ODE-206)	Sep 27, 2025
Orphan Drug Exclusivity(ODE-213)	Sep 27, 2025

Drugs and Companies using DACOMITINIB ingredient

NCE-1 date: 27 September, 2022

Market Authorisation Date: 27 September, 2018

Treatment: Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib or erlotinib resistant metastatic nsclc with egfr exon 19 deletion...

Dosage: TABLET

VIZIMPRO family patents

23. Wakix patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8354430	HARMONY	Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine	Feb, 2026 (22 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-846)	Oct 13, 2023
New Chemical Entity Exclusivity(NCE)	Aug 14, 2024
Orphan Drug Exclusivity(ODE-255)	Aug 14, 2026
New Patient Population(NPP)	Jun 21, 2027
Orphan Drug Exclusivity(ODE-331)	Oct 13, 2027
Orphan Drug Exclusivity(ODE-489)	Jun 21, 2031

Drugs and Companies using PITOLISANT HYDROCHLORIDE ingredient

NCE-1 date: 15 August, 2023

Market Authorisation Date: 14 August, 2019

Treatment: Method of treating cataplexy in patients with narcolepsy

Dosage: TABLET

WAKIX family patents

24. Xifaxan patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8741904	SALIX	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Feb, 2026 (a day ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518949	SALIX	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Feb, 2026 (a day ago)
US10703763	SALIX	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Feb, 2026 (a day ago)
US9271968	SALIX	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Feb, 2026 (a day ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 24, 2013
Orphan Drug Exclusivity(ODE)	Mar 24, 2017
New Indication(I-709)	May 27, 2018

Drugs and Companies using RIFAXIMIN ingredient

Market Authorisation Date: 25 May, 2004

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults; Reduction in risk of overt hepatic encephalopathy (he) recurrence in adults

Dosage: TABLET

Strength	Submission Date	Expiration Date of Last Qualifying Patent	180-Day Status	First Applicant Approval	Generic Competition Status
25 mg / 5 mL 🔒 Unlock					None
25 mg / 5 mL 🔒 Unlock	04 Nov, 2004	03 Dec, 2021	Non-Forfeiture	31 Mar, 2010	Less

Strength	Dosage	Availability
EQ 150MG BASE	TABLET	Prescription
EQ 300MG BASE	TABLET	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP06720163A	2011-11-28	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	Granted and Under Opposition

Strength	Dosage	Availability
15MG	TABLET	Prescription
45MG	TABLET	Prescription
30MG	TABLET	Prescription

Strength	Dosage	Availability
EQ 4.45MG BASE	TABLET	Prescription
EQ 17.8MG BASE	TABLET	Prescription

Strength	Submission Date	Expiration Date of Last Qualifying Patent	180-Day Status	First Applicant Approval	Generic Competition Status
25 mg / 5 mL 🔒 Unlock	28 Jan, 2019	24 Jul, 2029			Less
25 mg / 5 mL 🔒 Unlock	18 Dec, 2015	02 Oct, 2029	Non-Forfeiture Non-Forfeiture		Less

Pharsight

Pharsight

Recently Expired Drugs

1. Abraxane patent expiration

ABRAXANE family patents

2. Advair Hfa patent expiration

ADVAIR HFA family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years. Get the exclusive patent insights now. Don't be the last to know. Download Report 3. Auvi-q patent expiration

AUVI-Q family patents

4. Briviact patent expiration

BRIVIACT family patents

5. Corlanor patent expiration

CORLANOR family patents

6. Corlanor patent expiration

CORLANOR family patents

7. Dexilant patent expiration

DEXILANT family patents

8. Dexilant Solutab patent expiration

DEXILANT SOLUTAB family patents

9. Dymista patent expiration

DYMISTA family patents

10. Elepsia Xr patent expiration

ELEPSIA XR family patents

11. Evzio patent expiration

EVZIO family patents

12. Evzio (autoinjector) patent expiration

EVZIO (AUTOINJECTOR) family patents

13. Flovent Hfa patent expiration

FLOVENT HFA family patents

14. Flyrcado patent expiration

FLYRCADO family patents

15. Jublia patent expiration

JUBLIA family patents

16. Kerydin patent expiration

KERYDIN family patents

17. Onzetra Xsail patent expiration

ONZETRA XSAIL family patents

18. Saxenda patent expiration

SAXENDA family patents

19. Skelaxin patent expiration

SKELAXIN family patents

20. Tekturna patent expiration

TEKTURNA family patents

21. Victoza patent expiration

VICTOZA family patents

22. Vizimpro patent expiration

VIZIMPRO family patents

23. Wakix patent expiration

WAKIX family patents

24. Xifaxan patent expiration

XIFAXAN family patents

Related content

Have Questions?

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Auvi-q patent expiration